Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms

Clinical trial NCT07684170 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07684170
Sponsor: Compass Therapeutics
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Neoplasm Neuroendocrine Carcinomas Neuroendocrine Tumors

Start date: 2026-09-01
Primary completion: 2028-09-01
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.